Clinical Trial Shows Wearable Defibrillator No Better Than Waiting for an ICD, If the Patient Wonʼt Wear It

2018 ◽  
Vol 48 (20) ◽  
pp. 153-154
Keyword(s):  
Clinical Trial ◽  
Wearable Defibrillator ◽  
Better Than

A Multicentric Clinical Trial Comparing Otocerol® with Cerumol® as Cerumenolytics

1978 ◽  
Vol 6 (3) ◽  
pp. 241-244 ◽  
Author(s):  
Gabriel Jaffé ◽  
Jack Grimshaw
Keyword(s):  
Clinical Trial ◽  
General Practitioners ◽  
Comparative Trial ◽  
Double Blind ◽  
Better Than

Fifteen general practitioners conducted a randomized, double-blind comparative trial of two cerumenolytics, namely, Otocerol® and Cerumol®. A total of 106 patients were entered into the study (fifty-three in each group). Otocerol was shown to be marginally better than Cerumol in all parameters evaluated.

scholarly journals Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial

2019 ◽  
Vol 71 (4) ◽  
pp. 933-943 ◽  
Author(s):  
Linda Batsa Debrah ◽  
Ute Klarmann-Schulz ◽  
Jubin Osei-Mensah ◽  
Bettina Dubben ◽  
Kerstin Fischer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Single Dose ◽  
Combination Treatment ◽  
Primary Outcome ◽  
Onchocerca Volvulus ◽  
Open Label ◽  
Annual Treatment ◽  
Repeated Doses ◽  
Better Than

Abstract Background Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone. Methods This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocercomata excised at 36 months. Results Posttreatment nodule histology showed that 15/135 (11.1%), 22/155 (14.2%), 35/154 (22.7%), and 20/125 (16.0%) living female worms had normal embryogenesis in the IVM annual, IVM semiannual, IVM+ALB annual, and IVM+ALB semiannual groups, respectively (P = .1229). Proportions of dead worms also did not differ between the 4 groups (P = .9198). Proportions of patients without MF at 36 months (1 year after the last treatment) were 35/56 (63%) after annual IVM, 42/59 (71%) after semiannual IVM, 39/64 (61%) after annual IVM+ALB, and 43/53 (81%) after semiannual IVM+ALB. Conclusions The combination treatment of IVM plus ALB was no better than IVM alone for sterilizing, killing adult worms, or achieving sustained MF clearance. However, semiannual treatment was superior to annual treatment for achieving sustained clearance of Onchocerca volvulus MF from the skin (P = .024). Clinical Trials Registration ISRCTN50035143

scholarly journals The Efficacy of Once-Daily Dose of Phenobarbital in Children with Generalized Tonic-Clonic Epilepsy

2018 ◽  
Vol 35 (7-8) ◽  
pp. 172-9
Author(s):  
Amril A. Burhany ◽  
Sofyan Ismael ◽  
Hardiono Pusponegoro
Keyword(s):  
Clinical Trial ◽  
Plasma Concentrations ◽  
Serum Levels ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Study Group ◽  
Once Daily ◽  
Daily Dose ◽  
Plasma Measurements ◽  
Better Than

In spite of its long half life, phenobarbital is still given twice-daily in the treatment of generalized tonic-clonic epilepsy. This study aims to determine if daily dose of phenobarbital given once differs to that given twice daily. Subjects of this unblinded controlled clinical trial were generalized tonic-clonic epilepsy patients ranging in age from 1-15 years. There were 40 study cases and 42 controls. We gave phenobarbital 4-6 mg/kg/day once-daily for study group and twice-daily dose for control group. History, physical and EEG examination and phenobarbital plasma measurements were obtained a t the beginning of the study and four weeks later. The ratio of the second to first phenobarbital plasma concentrations in the study group was 0.99 while in the control group it was 1.02. The proportion of seizure-free patients in the study group increased from 70% at the beginning to 85% at the end of study, and in the control group from 64.3% to 83.3%. Hyperactivity and irritability increased in both groups, and there were no significant differences in mean serum levels, seizures control, hyperactivity and irritability in both groups. Drowsiness was found in 50% of cases, but statistically significant decrease were found in study group. The compliance of the study group (92.5%) was significantly better than that of the control group (71.4%).

Clinical outcomes of patients enrolled in clinical trial compared with patients outside clinical trial in advanced gastric cancer.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 21-21
Author(s):  
Jaejoon Han ◽  
Jin Won Kim ◽  
Se Hyun Kim ◽  
Jeong-Ok Lee ◽  
Yu Jung Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Overall Survival ◽  
Clinical Trials ◽  
Metastatic Disease ◽  
Median Overall Survival ◽  
Phase 1 ◽  
Second Line ◽  
First Line ◽  
Better Than

21 Background: Participation in clinical trials gives patients with cancer a chance to receive potential benefits, such as experimental treatment, meticulous follow-up and toxicity managements. We aimed to assess the evidence that such an effect exists in patients with gastric cancer. Methods: Clinical characteristics and overall survival of patients with metastatic or recurrent gastric cancer who received fluoropyrimidine and platinum combination palliative chemotherapy within or outside clinical trials at tertiary referral hospital from January 2010 to December 2012 were retrospectively analyzed. Results: Of the 244 patients, 84 patients (34%) were enrolled in clinical trials. During the study period, 20 patients in four phase 3 trials, 54 patients in eight phase 2 trials and ten patients in two phase 1 trials were participated in clinical trials. Twenty patients (8%) at first-line and 64 patients (38%) at second-line or later were enrolled in clinical trials. Younger age (P = 0.014), metastatic disease (P = 0.015) and HER2 IHC status (P = 0.005) were correlated with participation in clinical trials. The median overall survival of patients who participated in clinical trials at first-line was better than those who did not participated in clinical trials, although it was not statistically significant (16 months and 11 months, respectively, P = 0.407). Number of participation in clinical trials was not associated with survival outcome (1 versus ≥ 2 trials: 15 months and 18 months, respectively, P = 0.545). Second-line chemotherapy was administered in 167 patients. The median overall survival of patients who participated in clinical trials at second-line or later was also better than those who did not participated in clinical trials, however, it was not statistically significant (9 months and 6 months, respectively, P = 0.101). Conclusions: Younger patients, metastatic disease, positive HER2 IHC status, and clinical setting of second-line or later were associated with more participation in clinical trials. The median overall survival was numerically longer in patients who were enrolled in the clinical trials although it was not statistically significant.

Comparative Clinical Trial of Amoxycillin and Chloramphenicol in the Treatment of Typhoid in Adults

1979 ◽  
Vol 7 (3) ◽  
pp. 247-252 ◽  
Author(s):  
C U Abengowe
Keyword(s):  
Clinical Trial ◽  
Hypersensitivity Reaction ◽  
Typhoid Fever ◽  
Randomized Clinical Trial ◽  
Strong Support ◽  
Temperature Response ◽  
Dosage Schedule ◽  
Comparative Clinical Trial ◽  
Relapse Rates ◽  
Better Than

A randomized clinical trial in sixty-two adult patients suffering from typhoid fever, proved by blood and marrow culture, showed that amoxycillin in a dosage schedule of 1 g 8-hourly orally for fourteen days was better than chloramphenicol with regard to clinical and temperature response and in respect of carriers and relapse rates. One patient developed a hypersensitivity reaction to amoxycillin which cleared on withdrawal of the drug. Success was achieved in 90% of cases. These findings lend very strong support to the value of amoxycillin as a superior alternative to chloramphenicol in the treatment of typhoid fever.

Validity of an Assumption Underlying the Confirmed Bleeding Day Measurement in an Experimental Clinical Trial

1979 ◽  
Vol 58 (2) ◽  
pp. 610-613 ◽  
Author(s):  
Trevor L.P. Watts
Keyword(s):  
Clinical Trial ◽  
Sources Of Error ◽  
Gingival Bleeding ◽  
Better Than

In a clinical trial involving gingival bleeding, one measurement proved far better than the others. It was assumed that this measurement would help to eliminate certain sources of error. This paper examines data from the trial which give support to the assumption.

scholarly journals Efficacy of Split-Dosing versus Conventional Bowel Preparation in Colonoscopy: A Randomized Clinical Trial

2018 ◽  
Vol 3 (10) ◽  
Author(s):  
Tikfu Gee ◽  
Nadia B Abdullah ◽  
Chin Wai Peng ◽  
Tong Sheau Wan ◽  
Minn Oominn ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bowel Preparation ◽  
Colonic Mucosa ◽  
Therapeutic Tool ◽  
Age And Gender ◽  
And Gender ◽  
Split Dosing ◽  
Secondary Referral Hospital ◽  
Better Than

Background: Colonoscopy is an indispensable investigative and therapeutic tool in colorectal conditions. The accuracy of colonoscopic diagnosis is dependent on the effectiveness of the bowel preparation and the visibility of the colonic mucosa. Objective: This study compares the efficacy of split-dosing bowel preparation compared to the conventional the single-day timing of bowel preparation, by measuring the quality of colonoscopy performed using a validated bowel cleanliness score. Methods: An endoscopist-blinded clinical trial was conducted over a period of three months through convenient sampling at the Surgery Out-Patient Clinic at a secondary referral hospital in Malaysia. Data were recorded prospectively on the timing of bowel preparation, colonoscopic view of bowel cleanliness, age, and gender. Results: There was a total of 110 subjects for both conventional and test groups. Demographic studies showed 63 (57.3%) patients were under 60 years old, 61(55.5%) were male, and 48 (44%) were Malays. For the patients undergoing colonoscopy, the majority of the 86 (78.2%) had good bowel preparation and 96 (87.3%) of them with high efficacy of bowel preparation. The timing of bowel preparation is significantly associated with the efficacy of the bowel preparation and the quality of the colonoscopy (p<0.05). Conclusion: We conclude that split-dosing bowel preparation is significantly better than conventional timing bowel preparation in improving both the efficacy of bowel preparation as well as the quality of colonoscopy.

Sign in / Sign up

Export Citation Format

Share Document